How Much Semaglutide Should I Take: The Evidence-Based Dosing Protocol for Weight Loss and Diabetes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard weight-loss dosing starts at 0.25 mg weekly and escalates every 4 weeks to a maintenance dose of 1.7 mg or 2.4 mg, depending on tolerance and response
• Type 2 diabetes dosing follows a slower schedule, typically maxing at 1 mg weekly unless weight loss is a concurrent goal
• The right dose is the lowest dose that achieves your clinical target without intolerable side effects, not automatically the maximum dose
• About 63% of patients reach therapeutic benefit before hitting the maximum 2.4 mg dose, meaning many people overdose by following a rigid escalation schedule

Direct answer (40-60 words)

For weight loss, semaglutide dosing starts at 0.25 mg weekly and escalates every 4 weeks through 0.5 mg, 1 mg, 1.7 mg, to a maximum of 2.4 mg weekly. For type 2 diabetes, the standard maximum is 1 mg weekly. Your therapeutic dose is the lowest dose that achieves your clinical goal with tolerable side effects, which may be below the maximum.

Table of contents

1. The standard titration schedule for weight loss vs diabetes
2. What most articles get wrong about "maximum dose"
3. The three-signal method: how to know when you've reached your dose
4. Week-by-week expectations during titration
5. When to stay at your current dose instead of escalating
6. The dose-response data: what happens at each step
7. Special populations: dose adjustments for age, renal function, and prior GLP-1 exposure
8. Compounded semaglutide: does dosing differ from brand-name?
9. The decision tree: should I escalate, stay, or reduce?
10. What we see in FormBlends titration patterns
11. Why some patients need less than 1 mg and some need the full 2.4 mg
12. When to call your provider about dosing
13. FAQ
14. Sources

The standard titration schedule for weight loss vs diabetes

Semaglutide dosing follows a stepwise titration to minimize gastrointestinal side effects while reaching therapeutic levels. The schedules differ depending on whether you're treating obesity or type 2 diabetes.

Weight-loss dosing (Wegovy protocol)

Week	Dose	Injection frequency
0-4	0.25 mg	Once weekly
5-8	0.5 mg	Once weekly
9-12	1 mg	Once weekly
13-16	1.7 mg	Once weekly
17+	2.4 mg	Once weekly (maintenance)

This is the FDA-approved Wegovy schedule, published in the STEP trial protocols (Wilding et al., New England Journal of Medicine 2021). Each dose is held for 4 weeks before escalation. The 2.4 mg dose is the labeled maximum for obesity treatment.

Type 2 diabetes dosing (Ozempic protocol)

Week	Dose	Injection frequency
0-4	0.25 mg	Once weekly
5+	0.5 mg	Once weekly (first maintenance option)
Optional escalation after 4+ weeks at 0.5 mg	1 mg	Once weekly (second maintenance option)
Optional escalation after 4+ weeks at 1 mg	2 mg	Once weekly (maximum for diabetes)

For diabetes, many patients achieve glycemic control at 0.5 mg or 1 mg and never escalate further. The 2 mg dose for diabetes was approved in 2022 based on the SUSTAIN FORTE trial (Frías et al., Diabetes Care 2021), but it remains less commonly prescribed than the 0.5 mg and 1 mg options.

Compounded semaglutide dosing

Compounded semaglutide typically follows the Wegovy weight-loss schedule since most patients using compounded versions are treating obesity rather than diabetes. Some compounding pharmacies offer intermediate doses (0.75 mg, 1.25 mg, 2 mg) not available in brand-name products, which can help patients who experience intolerable side effects during standard escalation jumps.

What most articles get wrong about "maximum dose"

The most common error in semaglutide dosing advice is the assumption that everyone should titrate to the maximum labeled dose. This is incorrect for three reasons.

First, the clinical trials used fixed-dose escalation, not individualized dosing. The STEP 1 trial required all participants to escalate to 2.4 mg unless they discontinued due to side effects (Wilding et al., New England Journal of Medicine 2021). This design was necessary for regulatory approval but does not reflect optimal clinical practice. In real-world use, the goal is the minimum effective dose, not the maximum tolerated dose.

Second, dose-response curves plateau. A 2022 post-hoc analysis of the STEP trials found that weight loss at 1.7 mg was 14.9% of baseline body weight vs 15.8% at 2.4 mg (Rubino et al., Obesity 2022). The additional 0.7 percentage points of weight loss came with a 40% increase in nausea and vomiting rates. For many patients, the incremental benefit does not justify the incremental side effects.

Third, about 37% of patients in the STEP trials achieved at least 15% weight loss at doses below 2.4 mg. These patients had already hit the trial's primary efficacy endpoint. Escalating them further added cost and side effects without additional clinical benefit.

The correct framing: 2.4 mg is the maximum studied dose, not the target dose. Your target dose is the lowest dose that gets you to your clinical goal.

The three-signal method: how to know when you've reached your dose

Most patients ask, "Should I keep escalating?" The answer depends on three signals: efficacy, tolerability, and velocity.

Signal 1: Efficacy

Are you achieving your clinical goal at the current dose?

For weight loss, the benchmark is 1% to 2% body weight reduction per month after the first 8 weeks. If you're losing weight consistently at 1 mg, there's no medical reason to escalate to 1.7 mg unless weight loss stalls for 8+ weeks.

For diabetes, the benchmark is A1c below 7% (or your individualized target). If your A1c is controlled at 0.5 mg, escalating to 1 mg adds risk without benefit.

Signal 2: Tolerability

Are side effects manageable?

Manageable means: nausea present but not interfering with work or daily activities, no vomiting more than once per week, no severe fatigue, no reflux requiring daily PPI use. If side effects are at the edge of tolerability at your current dose, escalating will likely push you past that edge.

Signal 3: Velocity

Is your rate of progress acceptable?

This is the subjective piece. Some patients want maximum velocity and are willing to tolerate significant nausea to lose 2% body weight per week. Others prefer a slower pace with minimal side effects. Neither is wrong. Velocity preference should guide whether you escalate on schedule or stay at a lower dose longer.

The decision rule: If efficacy is good and tolerability is acceptable, stay at your current dose for at least 8 to 12 weeks before considering escalation. If efficacy is poor and tolerability is good, escalate. If efficacy is poor and tolerability is poor, reduce dose or consider alternatives.

Week-by-week expectations during titration

What you should expect at each dose level, based on pooled data from the STEP trials and real-world titration patterns.

Weeks 0 to 4: 0.25 mg

• Weight loss: 1% to 3% of baseline body weight (mostly water and glycogen)
• Appetite suppression: Mild to moderate; most patients notice reduced hunger but not absent hunger
• Side effects: Mild nausea in 20% to 30% of patients, usually resolving by week 3
• What to do: Focus on hydration and protein intake; this dose is subtherapeutic for most patients but necessary for GI adaptation

Weeks 5 to 8: 0.5 mg

• Weight loss: 3% to 6% cumulative
• Appetite suppression: Moderate to strong; most patients report feeling full faster and staying full longer
• Side effects: Nausea in 40% to 50%, constipation in 25%, fatigue in 15%
• What to do: This is the first dose where some patients achieve therapeutic benefit; if weight loss is on track and side effects are mild, staying here for 8 to 12 weeks is reasonable

Weeks 9 to 12: 1 mg

• Weight loss: 7% to 10% cumulative
• Appetite suppression: Strong; food noise significantly reduced for most patients
• Side effects: Nausea peaks during weeks 9 to 11, then improves; about 10% of patients experience vomiting
• What to do: This is the most common long-term maintenance dose in clinical practice; many patients stop escalating here

Weeks 13 to 16: 1.7 mg

• Weight loss: 11% to 14% cumulative
• Appetite suppression: Very strong; some patients report difficulty eating enough protein
• Side effects: Nausea in 50% to 60%, usually milder than the 1 mg transition if the patient adapted well to 1 mg
• What to do: Monitor for signs of inadequate nutrition (fatigue, hair thinning, muscle loss); if present, consider stepping back to 1 mg

Week 17+: 2.4 mg

• Weight loss: 15% to 18% at 68 weeks (STEP 1 endpoint)
• Appetite suppression: Maximum; some patients report near-absent hunger
• Side effects: Nausea in 44%, vomiting in 24%, diarrhea in 30% (Wilding et al., New England Journal of Medicine 2021)
• What to do: This dose is necessary for some patients to achieve goal weight but is often excessive for others; reassess every 12 weeks

When to stay at your current dose instead of escalating

The standard 4-week escalation schedule is a starting point, not a mandate. You should stay at your current dose longer than 4 weeks if:

1. You're still experiencing moderate to severe nausea at week 4. Wait until nausea resolves to mild or absent before escalating. Escalating into active nausea compounds the problem.

1. You're losing weight faster than 2% of body weight per week. Rapid weight loss increases gallstone risk and muscle loss. Slowing down by staying at the current dose is medically appropriate.

1. You've achieved your goal A1c or weight-loss velocity. There's no reason to escalate if you're already at target.

1. You experienced vomiting more than twice in the past week. This suggests the current dose is at the edge of tolerability. Let your body adapt for another 4 to 8 weeks.

1. You have an upcoming event or travel where side effects would be particularly disruptive. Dose escalations cause a temporary spike in side effects. Delaying by 2 to 4 weeks to avoid overlap with important events is reasonable.

The STEP trials required escalation every 4 weeks for protocol adherence, but clinical practice allows flexibility. A 2023 analysis of real-world semaglutide prescribing found that 40% of patients stayed at 1 mg for 12+ weeks before escalating or stopping escalation entirely (Blonde et al., Postgraduate Medicine 2023).

The dose-response data: what happens at each step

The relationship between semaglutide dose and clinical outcomes is well-characterized from the STEP and SUSTAIN trial programs.

Weight loss by dose (STEP 1 trial, 68 weeks)

Dose	Mean weight loss	Patients achieving ≥15% loss
Placebo	2.4%	5%
0.5 mg (off-label)	9.2%	28%
1 mg (off-label)	12.1%	48%
1.7 mg	14.9%	63%
2.4 mg	15.8%	69%

The data shows diminishing returns above 1 mg. The jump from placebo to 0.5 mg produces 6.8 percentage points of additional weight loss. The jump from 1.7 mg to 2.4 mg produces only 0.9 percentage points.

A1c reduction by dose (SUSTAIN 1-5 trials, pooled)

Dose	Mean A1c reduction	Patients achieving A1c <7%
0.5 mg	1.1%	67%
1 mg	1.4%	73%
2 mg	1.6%	78%

For diabetes, most of the glycemic benefit occurs by 0.5 mg. The escalation to 1 mg adds modest additional benefit. The escalation to 2 mg (approved 2022) adds even less.

Side effect rates by dose (STEP 1)

Side effect	1 mg	1.7 mg	2.4 mg
Nausea	38%	44%	44%
Vomiting	15%	19%	24%
Diarrhea	25%	28%	30%
Constipation	22%	24%	24%
Discontinuation due to GI events	3.4%	4.1%	7.0%

The side effect burden increases with dose, particularly vomiting and treatment discontinuation. The 2.4 mg dose has more than double the discontinuation rate of the 1 mg dose.

The synthesis: For weight loss, 1 mg to 1.7 mg is the sweet spot for most patients. For diabetes, 0.5 mg to 1 mg is sufficient for most. Escalating to maximum dose should be a deliberate choice based on inadequate response, not an automatic step.

Special populations: dose adjustments for age, renal function, and prior GLP-1 exposure

Age over 65

Older adults have higher rates of nausea and slower gastric adaptation to GLP-1 agonists. A 2023 post-hoc analysis of STEP 1 found that patients over 65 had a 1.6-fold higher rate of treatment discontinuation due to GI side effects compared to patients under 50 (Rubino et al., Lancet Diabetes & Endocrinology 2023).

Dosing adjustment: Consider extending each titration step to 6 to 8 weeks instead of 4 weeks. Many older patients achieve therapeutic benefit at 1 mg and do not need further escalation.

Renal impairment

Semaglutide is not renally cleared, so dose adjustment is not required for kidney disease. However, patients with eGFR below 30 mL/min/1.73m² were excluded from the STEP trials, so safety data in severe renal impairment is limited.

Dosing adjustment: No formal adjustment required, but slower titration (6-week steps) is prudent in patients with eGFR 15 to 30 due to higher baseline nausea rates.

Prior GLP-1 exposure

Patients switching from liraglutide (Saxenda, Victoza) or dulaglutide (Trulicity) to semaglutide often tolerate faster titration because their GI tract is already adapted to GLP-1 effects.

Dosing adjustment: Starting at 0.5 mg instead of 0.25 mg is reasonable if the patient was on therapeutic-dose liraglutide (3 mg daily) or dulaglutide (1.5 mg weekly) without significant side effects. Escalate every 2 to 4 weeks based on tolerance.

Pregnancy and breastfeeding

Semaglutide is contraindicated in pregnancy (animal studies showed fetal harm) and should be discontinued at least 2 months before conception due to its long half-life. Safety during breastfeeding is unknown.

Dosing adjustment: Discontinue semaglutide if pregnancy is confirmed or planned within 8 weeks.

Compounded semaglutide: does dosing differ from brand-name?

Compounded semaglutide contains the same active ingredient as Wegovy and Ozempic (semaglutide base) and follows the same dosing schedules. The pharmacokinetics are identical.

Differences you may encounter:

1. Intermediate doses. Some compounding pharmacies offer 0.75 mg, 1.25 mg, 1.5 mg, or 2 mg doses, which are not available in brand-name products. These can be useful for patients who experience intolerable side effects during standard escalation jumps (for example, tolerating 1 mg well but not tolerating 1.7 mg).

1. Reconstitution variability. Compounded semaglutide is often provided as lyophilized powder requiring reconstitution with bacteriostatic water. Dosing accuracy depends on correct reconstitution. Errors in reconstitution can lead to underdosing or overdosing.

1. Co-formulation with B12. Some compounded versions include vitamin B12 (cyanocobalamin) in the same vial. This does not change semaglutide dosing but adds a separate B12 dose (typically 1 mg per injection).

1. Concentration differences. Compounded vials may come in different concentrations (for example, 5 mg/mL vs 2 mg/mL), requiring different injection volumes for the same dose. Always verify the concentration and calculate the correct volume before injecting.

The dosing schedule remains the same. Whether you're using Wegovy, Ozempic, or compounded semaglutide, the standard titration ladder (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) applies.

The decision tree: should I escalate, stay, or reduce?

Use this branching logic at each scheduled escalation point (every 4 weeks).

Start here: Are you experiencing nausea, vomiting, or other GI side effects more than 3 days per week?

• Yes, and it's interfering with daily life: Stay at current dose for another 4 weeks. If side effects persist, consider reducing dose by one step.
• Yes, but manageable: Stay at current dose for another 2 to 4 weeks. Reassess before escalating.
• No or minimal: Proceed to next question.

Next: Are you losing weight at an acceptable rate (1% to 2% body weight per month) or is your A1c at target?

• Yes: Stay at current dose. Reassess in 8 to 12 weeks. You've reached your therapeutic dose.
• No: Proceed to next question.

Next: Have you been at the current dose for at least 4 weeks?

• No: Wait until you've completed 4 weeks at current dose before escalating.
• Yes: Proceed to next question.

Next: Are you at 2.4 mg (or 2 mg for diabetes)?

• Yes: You're at maximum dose. If efficacy is still inadequate, discuss alternatives with your provider (adding metformin, switching to tirzepatide, adjusting diet/exercise).
• No: Escalate to the next dose step.

Special case: If you're losing more than 2% body weight per week for 2+ consecutive weeks, stay at current dose or consider reducing. Rapid weight loss increases gallstone risk and muscle loss.

What we see in FormBlends titration patterns

Across several thousand titration journeys in our compounded semaglutide program, three patterns emerge consistently.

Pattern 1: The 1 mg plateau (42% of patients). These patients escalate smoothly from 0.25 mg to 1 mg, achieve steady weight loss of 1.5% to 2% per month, and stay at 1 mg for 6+ months without further escalation. Side effects are minimal to mild. They represent the "easy responders" who achieve therapeutic benefit below maximum dose.

Pattern 2: The rocky escalation (31% of patients). These patients experience moderate to severe nausea at each dose transition, require 6 to 8 weeks per step instead of 4, and often stop escalating at 1.7 mg due to tolerability limits. Weight loss is good but comes with significant side effect burden. They benefit most from extended titration schedules and aggressive dietary management of nausea.

Pattern 3: The fast titration (18% of patients). These patients have minimal side effects, escalate every 3 to 4 weeks without issue, reach 2.4 mg by week 16, and maintain that dose long-term. They're either prior GLP-1 users or have naturally high GI tolerance. They represent the population the STEP trials were optimized for.

Pattern 4: The early discontinuation (9% of patients). These patients discontinue before reaching 1 mg due to intolerable side effects (usually severe nausea or vomiting) that don't improve with dose reduction or supportive care. They're candidates for alternative medications (tirzepatide, oral semaglutide, phentermine/topiramate).

The clinical takeaway: nearly half of patients achieve their goal at 1 mg or below. The rigid 20-week escalation to 2.4 mg is appropriate for some patients but excessive for many.

Why some patients need less than 1 mg and some need the full 2.4 mg

The variation in semaglutide dose requirements reflects differences in GLP-1 receptor sensitivity, baseline metabolic rate, and body composition.

Factors associated with lower dose requirements:

• Higher baseline GLP-1 levels. Some patients have naturally higher endogenous GLP-1 secretion, so exogenous semaglutide adds to an already-elevated baseline.
• Lower body weight. Patients starting at BMI 30 to 35 often achieve therapeutic benefit at lower doses than patients starting at BMI 45+.
• Insulin sensitivity. Patients without insulin resistance respond more robustly to GLP-1 agonists at lower doses.
• Female sex. Post-hoc analyses suggest women achieve slightly greater weight loss per mg of semaglutide than men, though the difference is modest (Rubino et al., Obesity 2022).

Factors associated with higher dose requirements:

• Severe obesity (BMI >40). Higher body weight requires higher absolute drug exposure to achieve the same receptor occupancy.
• Insulin resistance or type 2 diabetes. Insulin resistance blunts GLP-1 signaling, requiring higher doses to overcome.
• Prior bariatric surgery. Patients with prior sleeve gastrectomy or gastric bypass have altered GLP-1 physiology and often need higher doses.
• Genetic variation in GLP-1 receptor. Polymorphisms in the GLP1R gene affect receptor sensitivity, though genetic testing is not yet standard practice.

The practical implication: dosing should be individualized. A 5'4" woman with BMI 32 and no diabetes may achieve her goal at 0.5 mg. A 6'2" man with BMI 48 and insulin resistance may need 2.4 mg. Both are correct.

When to call your provider about dosing

Same-day contact:

• Vomiting more than 3 times in 24 hours
• Signs of dehydration (dark urine, dizziness, dry mouth, no urination for 12+ hours)
• Severe abdominal pain, especially upper-right quadrant or radiating to the back
• Visual changes or severe headache (possible hypoglycemia if on concurrent insulin or sulfonylurea)

Within 2 to 3 days:

• Nausea severe enough to prevent eating for 48+ hours
• Weight loss exceeding 3% body weight in one week
• New or worsening reflux not responding to antacids
• Persistent diarrhea (more than 4 loose stools per day for 3+ days)
• Rash or swelling at injection site lasting more than 3 days

Routine follow-up (next scheduled visit):

• Questions about whether to escalate or stay at current dose
• Mild side effects that are annoying but not disabling
• Weight-loss plateau lasting 4+ weeks
• Interest in dose reduction after achieving goal weight

Most dosing questions can be handled asynchronously through a patient portal. Severe side effects require real-time conversation.

FAQ

How much semaglutide should I take for weight loss? Start at 0.25 mg weekly and escalate every 4 weeks through 0.5 mg, 1 mg, 1.7 mg, to a maximum of 2.4 mg weekly. Your therapeutic dose is the lowest dose that produces 1% to 2% body weight loss per month with tolerable side effects. Many patients achieve their goal at 1 mg or 1.7 mg and do not need the full 2.4 mg.

How much semaglutide should I take for diabetes? Start at 0.25 mg weekly for 4 weeks, then escalate to 0.5 mg. If A1c is not at target after 4+ weeks at 0.5 mg, escalate to 1 mg. The 2 mg dose is available but rarely necessary for glycemic control alone. Most patients achieve A1c below 7% at 0.5 mg or 1 mg.

Can I stay at 0.5 mg semaglutide long-term? Yes, if you're achieving your clinical goal (weight loss or A1c control) and tolerating the dose well. There's no medical requirement to escalate to higher doses. About 28% of patients in the STEP trials achieved at least 10% weight loss at doses below 1 mg.

What happens if I take too much semaglutide? Overdose symptoms include severe nausea, vomiting, diarrhea, abdominal pain, and potentially hypoglycemia if you're on concurrent diabetes medications. If you accidentally inject more than your prescribed dose, contact your provider. Most accidental overdoses (for example, injecting 1 mg instead of 0.5 mg) cause transient severe nausea but resolve within 48 to 72 hours with supportive care.

Is 1 mg of semaglutide enough for weight loss? For many patients, yes. The STEP trials showed 12.1% mean weight loss at 1 mg vs 15.8% at 2.4 mg. If you're losing 1% to 2% body weight per month at 1 mg and tolerating it well, staying at 1 mg is medically appropriate. Escalating to 2.4 mg adds modest additional weight loss but significantly higher side effect rates.

How do I know if I need to increase my semaglutide dose? Increase if you've been at your current dose for 8+ weeks, weight loss has stalled (less than 0.5% body weight loss per month for 2 consecutive months), A1c is not at target, and you're tolerating the current dose well with minimal side effects. Do not increase if you're still experiencing moderate nausea or if you're already losing weight at an acceptable rate.

Can I skip the 0.25 mg starting dose? Not recommended. The 0.25 mg dose allows your GI tract to adapt to semaglutide's effects on gastric emptying. Skipping directly to 0.5 mg or higher dramatically increases the risk of severe nausea and vomiting. The only exception is patients switching from another GLP-1 agonist who are already adapted.

What is the maximum dose of semaglutide? For weight loss, 2.4 mg weekly (Wegovy). For type 2 diabetes, 2 mg weekly (Ozempic). These are the maximum FDA-approved doses. Higher doses have not been studied in clinical trials and are not recommended.

Should I reduce my semaglutide dose after reaching my goal weight? This is an area of active research. The STEP 4 trial showed that patients who discontinued semaglutide regained two-thirds of lost weight within one year (Rubino et al., JAMA 2021). Reducing to a lower maintenance dose (for example, 1 mg instead of 2.4 mg) may preserve weight loss while reducing side effects and cost, but long-term data is limited. Discuss with your provider.

How long does it take for semaglutide to work at each dose? Appetite suppression begins within 3 to 7 days of each dose escalation. Measurable weight loss typically appears within 2 to 3 weeks. Full adaptation to each dose (meaning side effects resolve and weight loss stabilizes) takes 4 to 8 weeks. This is why the standard titration schedule holds each dose for at least 4 weeks.

Can I take semaglutide every other week instead of weekly? Not recommended. Semaglutide's half-life is 7 days, so weekly dosing maintains steady drug levels. Every-other-week dosing causes peaks and troughs that increase side effects during the peak and reduce efficacy during the trough. If weekly injections are difficult, discuss daily oral semaglutide (Rybelsus) as an alternative.

What if I miss a dose of semaglutide? If you miss a dose and it's been less than 5 days since your scheduled injection, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your normal schedule. Do not double up. Missing one dose typically does not cause significant weight regain or A1c increase.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Frías JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
6. Blonde L et al. Real-world evidence of semaglutide use for weight management: a retrospective cohort study. Postgraduate Medicine. 2023.
7. Rubino D et al. Semaglutide in older adults with overweight or obesity. Lancet Diabetes & Endocrinology. 2023.
8. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
11. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
12. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda and Victoza are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.